Company intelligence / Profile preview

BeamOne

Redmond, Washington, USA

Ownership: Private
Development stage: Other

Overview

BeamOne was a medical technology company focused on improving the safety of the global blood supply through advanced pathogen reduction systems. The company developed a proprietary platform that utilized electron beam (E-beam) irradiation to inactivate viruses, bacteria, and parasites in blood components like platelets and plasma. Unlike chemical-based methods, BeamOne's technology targeted the nucleic acids of pathogens without requiring the addition of external compounds, thereby maintaining the quality of the blood products. The company was acquired by Fenwal in 2009 to integrate its E-beam technology into a broader portfolio of transfusion medicine products.

Therapeutic areas: HematologyInfectious Diseases
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on BeamOne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BeamOne.

Explore the full profile